ExoScout Competitors

Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics, a new class of custom-built drugs for medical challenges other modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zürich, Switzerland and Concord, MA, USA.

Science Exchange is the first purchasing and supplier orchestration platform for life sciences companies. We’re on a mission to streamline and modernize the way R&D organizations and suppliers work together. Our platform harmonizes purchasing, supplier management, and payment processing through one platform and digital marketplace. Whether using our network of 3,800 suppliers with established contracts or syncing existing ones, a simple intake process enables scientists to purchase the services and products they need while workflows and integrations guide them through approvals and compliance requirements. Science Exchange ensures supplier data integrates into ELNs and the secure transfer of large files to enhance supplier collaboration. The platform also employs an automated payment system to validate all invoices and provide prompt supplier payment. The world’s top life sciences companies, including BMS, AbbVie, Gilead, and Astellas, rely on Science Exchange to help accelerate their research, automate manual processes, and advance their programs faster.

CureMetrix is committed to the advancement of technology that improves disease detection and survival rates worldwide. Our AI-based products and research are focused on leveraging artificial intelligence and deep learning to develop the next generation of medical image analysis technology that radiologists and patients can confidently rely on. Today, our powerful image analysis platform is an adjunct, precision tool for mammography. Our goal is to equip radiologists with the objective, data-driven answers they need to support patients and their healthcare team as they make decisions about their health. At CureMetrix, we believe that providing radiologists with the most advanced technology to support their evaluation of mammograms will lead to improved clinical outcomes, reduced healthcare costs, and increased assurance that patients are getting the highest standard of care available from screening. Over the last 10 years since our founding in 2014, we have focused on building products with extremely high efficacy that are easy to install, operate within existing clinical workflows, and minimize extra steps from radiologists and patients. CureMetrix has partnered with practicing radiologists, cardiologists, and esteemed institutions around the world to collect over 5 million images to train and validate our algorithms. From breast cancer to heart disease to kidney disease we believe that AI can be used to improve outcomes for patients and extend the impact and value of screening programs globally.